UnifiedACB

Medication evidence profile

Leuprolide

Ask about Leuprolide

Clinical overview

Leuprolide has public medication-list entries in Swe-ABS 2023, GABS 2018, and KABS 2020 open validation supplement. These are 3 separate source versions, each with its own evidence and definitions.

Source-specific scores

SourceScore
JARSNot listed
Yamada-ABSNot listed
BAASNot listed
Swe-ABS0
GABS0
KABS0
CALSNot listed

How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.

How to interpret the evidence

3 of 7 public source versions contain an explicit medication-list entry for leuprolide.

The available rows for leuprolide display the same numeric value. Agreement of the displayed numbers does not establish identical methods, clinical meaning or patient-level risk.

Swe-ABS 2023, GABS 2018, and KABS 2020 open validation supplement explicitly record zero. Those recorded zeros remain different from a missing entry.

Source labels and provenance · 3 observations
  1. Swedish Anticholinergic Burden Scale 2023

    Source label: Leuprolide. Published value: 0.
    Source version: SWE-ABS-2023
    Source location: 12877_2023_4225_MOESM1_ESM.docx ST3 row 134
    Observation: SWE_ABS_2023_R0259; rating state: published_zero.

  2. German Anticholinergic Burden Score 2018

    Source label: Leuprolide. Published value: 0.
    Source version: GABS-2018
    Source location: 12877_2018_929_MOESM1_ESM.docx Table S3 row 189
    Observation: GABS_2018_R0339; rating state: published_zero.

  3. KABS 2019 scale - 2020 open validation supplement

    Source label: Leuprolide. Published value: 0.
    Source version: KABS-2020-validation-supplement
    Source location: Additional file 1; category Antineoplastic and immunomodulating agents; table row 31
    Observation: KABS2020_SUPP_0155; rating state: published_zero.

What this page does not establish

  • No medication-list entry is available here from JARS 2025, Yamada-ABS 2023, BAAS 2019, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
  • No route inference unless present in the source label.
  • These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.

References

  1. Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
  2. Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
  3. Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source

Ask a follow-up

Go to your medication comparison · How UnifiedACB handles disagreement

Ask about this medication

Medication context: Leuprolide

Ask about this medication
Show Leuprolide across all available scalesWhy do the scales differ for Leuprolide?Show the evidence for LeuprolideCompare Leuprolide with another medication